Recalcitrant Atopic Dermatitis Treated with Omalizumab.
- Author:
Se Young PARK
1
;
Mi Ra CHOI
;
Jung Im NA
;
Sang Woong YOUN
;
Kyoung Chan PARK
;
Chang Hun HUH
Author Information
- Publication Type:Case Report
- Keywords: Atopic dermatitis; Biologies; Omalizumab
- MeSH: Adult; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal, Humanized; Binding Sites; Dermatitis, Atopic; Humans; Immunoglobulin E; Korea; Omalizumab
- From:Annals of Dermatology 2010;22(3):349-352
- CountryRepublic of Korea
- Language:English
- Abstract: Atopic dermatitis (AD) is a chronic cutaneous inflammatory disease. Various categories of therapeutic medications are used for treating AD. Omalizumab is a monoclonal anti-IgE antibody that binds to IgE molecules at the high-affinity receptor (FcepsilonRI) binding site. Therefore, omalizumab can be used as a potential new systemic treatment agent for recalcitrant AD patients with elevated IgE levels. A 34-year-old man had been treated for AD with several topical and oral agents. However, he was refractory to these therapies and his serum IgE levels were very high. We treated him with omalizumab. After 8 months of the treatment, his symptoms were notably improved and the SCORAD index was decreased. Thus, we report on the first case of recalcitrant AD that was successfully treated with omalizumab in Korea.
